Literature DB >> 9050839

Conformation-dependent phosphorylation of p53.

V Adler1, M R Pincus, T Minamoto, S Y Fuchs, M J Bluth, P W Brandt-Rauf, F K Friedman, R C Robinson, J M Chen, X W Wang, C C Harris, Z Ronai.   

Abstract

Phosphorylation of the p53 tumor suppressor protein is known to modulate its functions. Using bacterially produced glutathione S-transferase (GST)-p53 fusion protein and baculovirus-expressed histidine-tagged p53 ((His)p53), we have determined human p53 phosphorylation by purified forms of jun-N-kinase (JNK), protein kinase A (PKA), and beta subunit of casein kinase II (CKIIbeta) as well as by kinases present in whole cell extracts (WCEs). We demonstrate that PKA is potent p53 kinase, albeit, in a conformation- and concentration-dependent manner, as concluded by comparing full-length with truncated forms of p53. We further demonstrate JNK interaction with GST-p53 and the ability of JNK to phosphorylate truncated forms of GST-p53 or full-length (His)p53. Dependence of phosphorylation on conformation of p53 is further supported by the finding that the wild-type form of p53 (p53wt) undergoes better phosphorylation by CKIIbeta and by WCE kinases than mutant forms of p53 at amino acid 249 (p53(249)) or 273 (p53(273)). Moreover, shifting the kinase reaction's temperature from 37 degrees C to 18 degrees C reduces the phosphorylation of mutant p53 to a greater extent than of p53wt. Comparing truncated forms of p53 revealed that the ability of CKIIbeta, PKA, or WCE kinases to phosphorylate p53 requires amino acids 97-155 within the DNA-binding domain region. Among three 20-aa peptides spanning this region we have identified residues 97-117 that increase p53 phosphorylation by CKIIbeta while inhibiting p53 phosphorylation by PKA or WCE kinases. The importance of this region is further supported by computer modeling studies, which demonstrated that mutant p53(249) exhibits significant changes to the conformation of p53 within amino acids 97-117. In summary, phosphorylation-related analysis of different p53 forms in vitro indicates that conformation of p53 is a key determinant in its availability as a substrate for different kinases, as for the phosphorylation pattern generated by the same kinase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9050839      PMCID: PMC19977          DOI: 10.1073/pnas.94.5.1686

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Phosphorylation of the p53 tumour-suppressor protein at three N-terminal sites by a novel casein kinase I-like enzyme.

Authors:  D M Milne; R H Palmer; D G Campbell; D W Meek
Journal:  Oncogene       Date:  1992-07       Impact factor: 9.867

2.  On the multiple-minima problem in the conformational analysis of polypeptides. II. An electrostatically driven Monte Carlo method--tests on poly(L-alanine).

Authors:  D R Ripoll; H A Scheraga
Journal:  Biopolymers       Date:  1988-08       Impact factor: 2.505

3.  The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation.

Authors:  M Reed; B Woelker; P Wang; Y Wang; M E Anderson; P Tegtmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

4.  Phorbol esters stimulate the phosphorylation of c-Jun but not v-Jun: regulation by the N-terminal delta domain.

Authors:  V Adler; C C Franklin; A S Kraft
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

5.  The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II.

Authors:  D W Meek; S Simon; U Kikkawa; W Eckhart
Journal:  EMBO J       Date:  1990-10       Impact factor: 11.598

6.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

Review 7.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

8.  Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53.

Authors:  S P Lees-Miller; K Sakaguchi; S J Ullrich; E Appella; C W Anderson
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

9.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation.

Authors:  S J Kuerbitz; B S Plunkett; W V Walsh; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

10.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

Authors:  M B Kastan; Q Zhan; W S el-Deiry; F Carrier; T Jacks; W V Walsh; B S Plunkett; B Vogelstein; A J Fornace
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

View more
  36 in total

1.  Cytoplasmic c-Jun N-terminal immunoreactivity: a hallmark of retinal apoptosis.

Authors:  Luciana B Chiarini; Fabíola G de Freitas; Mona Lisa Leal-Ferreira; Aviva Tolkovsky; Rafael Linden
Journal:  Cell Mol Neurobiol       Date:  2002-12       Impact factor: 5.046

2.  Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins.

Authors:  Najma Begum; Steven Hockman; Vincent C Manganiello
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

3.  Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.

Authors:  P De Feudis; S Vignati; C Rossi; T Mincioni; R Giavazzi; M D'Incalci; M Broggini
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

Review 4.  Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases.

Authors:  Marie A Bogoyevitch; Bostjan Kobe
Journal:  Microbiol Mol Biol Rev       Date:  2006-12       Impact factor: 11.056

5.  Activation of cAMP signaling interferes with stress-induced p53 accumulation in ALL-derived cells by promoting the interaction between p53 and HDM2.

Authors:  Elin Hallan Naderi; Aart G Jochemsen; Heidi Kiil Blomhoff; Soheil Naderi
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

6.  JNK targets p53 ubiquitination and degradation in nonstressed cells.

Authors:  S Y Fuchs; V Adler; T Buschmann; Z Yin; X Wu; S N Jones; Z Ronai
Journal:  Genes Dev       Date:  1998-09-01       Impact factor: 11.361

7.  Stabilization and activation of p53 are regulated independently by different phosphorylation events.

Authors:  M V Chernov; C V Ramana; V V Adler; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

8.  MEKK1/JNK signaling stabilizes and activates p53.

Authors:  S Y Fuchs; V Adler; M R Pincus; Z Ronai
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

9.  A role for c-Jun N-terminal kinase 1 (JNK1), but not JNK2, in the beta-amyloid-mediated stabilization of protein p53 and induction of the apoptotic cascade in cultured cortical neurons.

Authors:  Marie P Fogarty; Eric J Downer; Veronica Campbell
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

10.  Reciprocal regulation of glutathione S-transferase spliceforms and the Drosophila c-Jun N-terminal kinase pathway components.

Authors:  Rungrutai Udomsinprasert; Marie A Bogoyevitch; Albert J Ketterman
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.